转移性肾癌靶向治疗和免疫治疗的现状与进展  

Current status and progress of targeted treatment and immunotherapy for metastatic renal cell carcinoma

作　　者：吴海欧 于常华[1] Wu Haiou;Yu Changhua(Department of Medical Oncology,the Second Affliated Hospital of Harbin Medical Univercity,Heilongjiang Harbin 150086,China.)

机构地区：[1]哈尔滨医科大学附属第二医院肿瘤内科

出　　处：《现代肿瘤医学》2019年第21期3920-3922,共3页Journal of Modern Oncology

摘　　要：近年来,转移性肾癌的治疗方式从细胞因子药物的治疗,到现在的针对血管生成、哺乳动物的雷帕霉素途径、免疫应答的药物的应用发生了巨大的变化。尽管耐药仍然是一个巨大的挑战,但通过对这些药物的应用及药物联合应用,转移性肾癌的治疗疗效得到大大的提高。目前新的治疗方法正在迅速发展,治疗前景一片大好。In recent years,the treatment of metastatic renal cell carcinoma has changed dramatically from the treatment of cytokine drugs to the current use of drugs for angiogenesis,mammalian rapamycin pathways,and immune responses.Although resistance is still a huge challenge,the therapeutic effects of metastatic renal cell carcinoma have been greatly improved through the application of these drugs and the combination of drugs.At present,new treatment methods are developing rapidly,and the treatment prospects are expected to further develop.

关 键 词：转移性肾癌 靶向治疗 免疫治疗 

分 类 号：R737.11[医药卫生—肿瘤]